Vivos Therapeutics (VVOS) Assets (2019 - 2026)

Vivos Therapeutics (VVOS) has reported Assets for 8 consecutive years, with $24.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets fell 7.26% year-over-year to $24.1 million in Q2 2026; TTM through Jun 2026 was $24.1 million, a 7.26% decrease from a year earlier, with the FY2025 full-year figure at $25.2 million, up 64.56% from the prior year.
• Assets was $24.1 million for Q2 2026 at Vivos Therapeutics, down from $25.0 million in the prior quarter.
• Over five years, Assets peaked at $29.6 million in Q1 2022 and troughed at $10.3 million in Q3 2023.
• A 5-year average of $18.5 million and a median of $16.5 million in 2023 frame the typical range for Assets.
• Across the five-year window, Assets slumped 59.27% in 2022 and jumped 121.97% in 2026, its largest moves.
• Over 5 years, Assets stood at $13.7 million in 2022, then dropped by 21.79% to $10.7 million in 2023, then soared by 42.44% to $15.3 million in 2024, then jumped by 64.56% to $25.2 million in 2025, then slipped by 4.01% to $24.1 million in 2026.
• The last three Assets figures came in at $24.1 million (Q2 2026), $25.0 million (Q1 2026), and $25.2 million (Q4 2025), per Business Quant data.